Pretreatment and Treatment Evaluation: 
Pretreatment evaluation will consist of a complete history and physical including 
performance status, weight loss, description of previous and current malignant and non- 
malignant diseases and their treatment, and residual toxicities; location and size of the 
endobronchial lesion; chest x-ray, and laboratory studies including: quantitative 
immunoglobulins; a CBC with differential and platelet count; SMA-12 and electrolytes, 
including creatinine, bilirubin, SGPT, alkaline phosphatase, and urinalysis. 
Prior to each course of therapy, the following clinical data will be ascertained and 
recorded: 
1. CBC, platelet count, PT, PTT, SMA-12, electrolytes, and a chest x-ray. 
2. Measurement and bronchoscopic photograph of tumor. 
3. All relevant information regarding drug dosage, tumor response, laboratory 
examinations, and treatment-related toxicities. 
Mi scellaneous Information: 
Not applicable. 
St atistical Considerations: 
The primary endpoint of the study will be regrowth of the tumor. The effect of therapy in 
this group of patients will also be measured by determining length of patient survival, 
length of time the affected lobe of the lung remains aerated, and reduction in measurable 
endobronchial tumor. A maximum of 14 patients will be recruited in this study. 
Jb jectives: 
The objective of this protocol is to evaluate the toxicity and possible therapeutic efficacy 
of the intralesional administration of retroviral constructs containing antisense (AS) K-ras 
(for tumors with mutated K-ras) and wildtype p53 (y\i\p53) (for tumors with mutated or 
deleted p53) into residual endobronchial NSCLC which obstructs a bronchus and which is 
refractory to conventional therapy. 
Recombinant DNA Research, Volume 19 
[277] 
